Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 16 February 2021 regarding the commencement of the
subscription period in the planned subsequent offering and parallel employee
offering, both consisting of an issuance of up to 181,818 new shares in the
Company (the "Subsequent Offering") (the "Employee Offering").

Primary insider Claus Seeberg, though his holding company CS Holding AS has
committed to subscribe for NOK 293 150 in the Subsequent Offering.

The shares in the Subsequent offering will be allocated by the Board of
Directors and issued under a board authorization granted by the Company's
general meeting held on 4 January 2021. The shares in the Subsequent Offering
will be allocated by the Board of Directors and will be issued in accordance
with the resolution made by the Company's general meeting held on 4 January
2021. 

For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth)
is a Norwegian MedTech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR), biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com